China Biologic Completes $468 Million Follow-On Offering

On March 7, 2016, China Biologic Products, Inc., a leading plasma-based biopharmaceutical company in China, completed its follow-on public offering with an aggregate offer size of more than $468 million, consisting of 4,257,000 shares of common stock sold by entities affiliated with Warburg Pincus, the selling stockholders, at a price to the public of $110 per share. China Biologic did not sell any shares of common stock or receive any proceeds from the sale in the offering.

Wilson Sonsini Goodrich & Rosati represented China Biologic and the selling stockholders in connection with the offering. Morgan Stanley & Co. International acted as the sole book-running manager for the offering.

The WSGR team was led by partners Weiheng Chen and Jie Zhu, and included Jing Xu, Ke Li, and Long Li.

For more information, please see the China Biologic's press release.